1,3-dmaa - Rubraca (Rucaparib Camsylate) Interaction
Herbal: 1,3-dmaa
Also Known As: DMAA, Dimethylamylamine
Drug: Rucaparib Camsylate
Brand names:
Rubraca
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
May 04, 2025
Interaction Details
Rucaparib Camsylate is classified as belonging to the following category: Cytochrome P450 2D6 (Cyp2D6) Substrates
1,3-DMAA strongly inhibits cytochrome P450 2D6 (CYP2D6) enzymes in vitro. Theoretically, 1,3-DMAA can increase levels of CYP2D6 substrates. Some of drugs that are CYP2D6 substrates include amitriptyline (Elavil), clozapine (Clozaril), codeine, desipramine (Norpramin), donepezil (Aricept), fentanyl (Duragesic), flecainide (Tambocor), fluoxetine (Prozac), meperidine (Demerol), methadone (Dolophine), metoprolol (Lopressor, Toprol XL), olanzapine (Zyprexa), ondansetron (Zofran), tramadol (Ultram), trazodone (Desyrel), and others.
Interaction Rating
Likelihood of Occurrence
PossibleInteraction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
References
- Liu Y, Santillo MF. Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements. Drug Test Anal. 2016;8(3-4):307-10.
1,3-dmaa Overview
1,3-Dimethylamylamine (DMAA) is a synthetic compound that was once used in dietary supplements, primarily for its purported stimulant effects. It was marketed as a performance-enhancing and weight-loss aid due to its similarities to amphetamines. However, DMAA has been banned or restricted in several countries due to safety concerns, including reports of adverse effects such as increased blood pressure, heart rate, and potential links to serious health issues like strokes and heart attacks. As a result, DMAA is no longer commonly found in legal dietary supplements.
Rucaparib Camsylate Overview
-
Rucaparib is used to help maintain the response to other treatments for certain types of ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer that has returned in adults who have completely responded or partially responded to other chemotherapy treatment(s). It is also used to treat certain types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer in people with a specific gene who have received treatment with at least two other chemotherapy treatments. Rucaparib is also used to treat certain types of prostate cancer that has spread to other areas in the body in people with a specific gene who have received other treatments. Rucaparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells.
1,3-dmaa - More Interactions
1,3-dmaa interacts with 319 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
| Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
| Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
| Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
| Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main supplement interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.
Ask A Pharmacist About Your Herbal Questions!
Dr. Brian Staiger, PharmD
In addition to being a clinical pharmacist specializing in pharmacotherapy, Dr. Brian Staiger is a registered herbalist through the American Herbalist Guild. He has combined his passion for pharmacy practice with the study of medical ethnobotany to improve patient care. Feel free to reach out about any of your herbal or medication questions!
Ask A Pharmacist